TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01607762

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone
Description: Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
Study: NCT00454740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: solifenacin succinate
Description: Oral
Study: NCT04286269

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Based Intervention
Description: Participants assigned to MBI will receive a total of 1.5 hours of music intervention 5-6 sessions per week. Music will be alternating: 30 minutes on and 30 minutes off and will be played when the subject is awake to cue pacification and initiate the sleep process. Music will be delivered through headphones using an MP3 player.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Treatment
Description: Participants assigned to the control group will have the same treatment as the MBI group, but with no sound played through the headphones.
Study: NCT00529789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: duloxetine
Description: 20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is \>40 kg, initial dose is 30 mg, then titrated up.
Study: NCT05101954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concentrated Growth Factors (CGF)
Description: Concentrated Growth Factors membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Platelet-Rich Fibrin (PRF)
Description: Platelet-Rich Fibrin (PRF) membrane will be laid in the implant cavity. Bone graft material will be applied to fill the empty parts of the socket.
Study: NCT03750214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biop Colposcopy System
Description: The procedure stages:~1. Scanning of the cervix - the cervix is scanned using the micro colposcope probe unit, to produce a total of 51 micro-images and one macro image from the panoramic camera.~2. Colposcopy exam - during the standard colposcopy exam, the doctor acquires a panoramic image of the cervix with the digital colposcope.~3. A questionnaire completed by the subject after the Biop procedure, with regards to any unusual sensations or events experienced during the procedure.~4. A questionnaire completed by the user after the Biop procedure, with regards to system usage~5. Image Registration analysis
Study: NCT02337036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacokinetic
Description: Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenetic
Description: Pharmacogenetic study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: These Patients are treated with tacrolimus after the Liver Transplantation
Study: NCT04768712

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight bearing aerobic exercise
Description: Weight bearing aerobic exercise three times per week.
Study: NCT04011813

Intervention type: OTHER
Intervention: Hypotaurine : antioxidant and osmoregulator
Description: Hypotaurine has protective effects on sperm motility, capacitation and acrosome reaction and reduces apoptotic markers.~Hypotaurine (50mM) was added in density gradient centrifugation, washing and cryopreservation media washing and cryopreservation media before spermatozoa freezing
Study: NCT03488745

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IntelliCare + Phone Coaching
Description: IntelliCare is composed of 13 separate, native apps. Each app targets a specific aspect of mental health (e.g., reducing worry, increasing social support, tracking negative thoughts). The apps are available to the public in both Android and iPhone stores. Participants will be asked to try two new IntelliCare apps every week, for 7 weeks. Phone coaching will occur at Day 0, before using any of the apps, and the third week of app usage.
Study: NCT01869179

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community of Voices choir program
Description: Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community of Voices choir program
Description: Attend weekly choir sessions for 12 months at the Senior Center. All choir sessions will include activities that focus on cognitive, psychosocial, and physical engagement components Choir sessions will last 90 minutes each with a 10 minute break. Take part in 3-4 informal choir concerts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wait-list control group
Study: NCT03753984

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: In both arms will be applied Low-level laser therapy and induced muscle fatigue.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy
Description: In both arms will be applied Low-level laser therapy and induced muscle fatigue.
Study: NCT01995903

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI(magnetic resonance imaging)
Description: Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI(magnetic resonance imaging)
Description: Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
Study: NCT02462759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nusinersen
Description: Administered by intrathecal injection.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham Procedure
Description: Small needle prick on the lower back at the location where the IT injection is normally made.
Study: NCT03262831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga
Description: The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
Study: NCT00590122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parcopa
Description: at subjects current stable dose of comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbidopa-levodopa (Sinemet)
Description: at subjects current stable dose
Study: NCT04077424

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone-High Dose Quadrivalent
Description: Seasonal influenza vaccination with FDA approved vaccines for this age group.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluad
Description: Adjuvanted (MF59) inactivated influenza vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Flublock
Description: Recombinant hemagglutinin vaccine
Study: NCT03536481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (test product)
Description: Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (test product)
Description: Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (test product)
Description: Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (test product)
Description: Test product(T)：100mg ensartinib capsules manufactured by Betta Pharmaceuticals

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (reference product)
Description: Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (reference product)
Description: Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (reference product)
Description: Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
Study: NCT03262831

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: * Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)
Study: NCT03536481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ensartinib capsules (reference product)
Description: Reference product(R)：100mg ensartinib capsules manufactured by Catalent Pharma Solutions
Study: NCT01370941

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Drug A Chymosin
Description: Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Drug B: Placebo
Description: B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
Study: NCT00241176

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS \& CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
Study: NCT00128024

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lipid-lowering treatment
Study: NCT04601207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis Preparation
Description: Dosed as a single oral dose
Study: NCT06053918

Intervention type: OTHER
Intervention: additional follow-up extension at home
Description: additional interview when leaving the sector, and the extension of follow-up of the patient at home
Study: NCT05948514

Intervention type: OTHER
Intervention: The complications related to central venous access device
Description: The complications related to central venous access device were collected when occurs : from time of catheter insertion, until first complication, or removal for another type of catheter, or until death.
Study: NCT04601207

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cannabis Preparation
Description: Dosed as a single oral dose
Study: NCT02220803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide
Description: Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal Continuous Positive Airway Pressure (nCPAP)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal Continuous Positive Airway Pressure (nCPAP)
Study: NCT02180204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenecteplase
Description: Tenecteplase 0.25 mg/kg IV - Maximum 25 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Alteplase 0.9 mg/kg IV - Maximum: 90 mg
Study: NCT00090961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention

Intervention type: OTHER
Group type: OTHER
Intervention: educational intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: supervised exercise program
Study: NCT01687543

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L. plantarum 299 and L. plantarum 299v (+maltodextrin)
Description: A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin
Description: A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
Study: NCT03262831

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood draw
Description: * Baseline and end of treatment~* To evaluate change in inflammatory markers (CRP, IL-6, and TNF)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FACT-G questionnaire
Description: * 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: FACT-G questionnaire
Description: * 7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days~* Answers range from 0=not at all to 4=very much

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Weight measurement
Description: -Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Weight measurement
Description: -Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recent Physical Activity Questionnaire
Description: -To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Recent Physical Activity Questionnaire
Description: -To assess physical activity, the RPAQ will be completed at baseline and at the end of treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NHANES Food Questionnaire
Description: -To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NHANES Food Questionnaire
Description: -To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of treatment.
Study: NCT01881412

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Asthma Discharge Instructions
Description: Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
Study: NCT03841526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glugaon RTU Injection Without Insulin Pump Reduction
Description: 0.15 mg injection without pump reduction
Study: NCT01715272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TF037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fleet enema
Study: NCT02648243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured intervention at discharge and tailored follow up post discharge
Description: At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.~The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge.
Study: NCT00948038

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Milk
Description: Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Soy
Description: Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
Study: NCT02715050

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active or Placebo Phototherapy (MR4)
Study: NCT04296916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP lowering eye drops
Description: 1. Latanoprost 0.005% eye drops will be the first choice. If an IOP reduction of 20% is not achieved within three months, timolol 0.5% will be added as second medication. If an IOP reduction of 20% is then not achieved, alphagan 0.2% or alphagan-P 0.15% will be added. If an IOP reduction of 20% is then not achieved, the individual will be excluded from the study.~2. If necessary, latanoprost will be switched to other prostaglandin eye drops, alphagan (or alphagan-P) will be switched to brinzolamide 1% eye drops.~3. If necessary, latanoprost and timolol will be switched to Xalacom eye drops, timolol and alphagan will be switched to Combigan eye drops, timolol and brinzolamide will be switched to Azarga eye drops.~4. Once daily in the evening for prostaglandin eye drops, and twice daily for other eye drops.
Study: NCT04516031

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior Component Separation with Transversus Abdominis Muscle Release
Description: The posterior component separation technique with transversus abdominis muscle release was done as prescribed in Novitsky et al in 2012.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mesh-only repair
Description: The prosthetic mesh only repair was done as described by Wantz in 1991.
Study: NCT01712503

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Phacoemulsfication cataract surgery and intra-ocular lens implant

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phacoemulsfication cataract surgery and intra-ocular lens implant
Study: NCT02695576

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Fusion Surgery
Description: Interbody fusion with fixation
Study: NCT01881412

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Asthma Discharge Instructions
Description: Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)